Chrysophanics

Other Names

1,8-Dihydroxy-3-methyl-9,10-anthracenedione1,8-Dihydroxy-3-methyl-9,10-anthraquinone1,8-dihydroxy-3-methyl-anthracene-9,10-dione1,8-Dihydroxy-3-methylanthra-9,10-quinone1,8-dihydroxy-3-methylanthracene-9,10-dione1,8-Dihydroxy-3-methylanthraquinone2-Methyl-4,5-dihydroxyanthraquinone3-Methyl-1,8-dihydroxyanthraquinone3-Methylchrysazin3-Methylchrysazine4,5-Dihydroxy-2-methylanthraquinone9,10-Anthracenedione, 1,8-dihydroxy-3-methyl-9,10-Anthracenedione, 1,8-dihydroxy-3-methyl- (9CI)Acido crisofanicoAcidum chrysophanicumAnthraquinone, 1,8-dihydroxy-3-methyl-ArchininC.I. 75400C.I. Natural Yellow 23Chrysophanic acidChrysophanolChrysophansaeureChrysophanureCrysophanic acidCrysophanolNatural Yellow 23Resinous yellow of wall lichensRhabarberic acidRheic acidRheineRhenic acidRheumineRhubarb yellowRhubarbarinRumicinTurkey rhubarb

Synopsis

Chrysophanics (Chrysophanic Acid / Chrysophanol): A Comprehensive Reference

1. Identity and Nomenclature

Chrysophanol, also known as chrysophanic acid, is a naturally occurring anthraquinone compound with a wide range of biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The term chrysophanics refers to this same compound and its preparations; in older pharmacopoeial and medical literature the name "chrysophanic acid" predominated, while modern biochemical and pharmacological literature predominantly uses "chrysophanol."

Chrysophanol (Chr), also known as 1,8-dihydroxy-3-methyl-anthraquinone, is a representative mono-nuclear compound with methyl substitution that plays a significant role in natural anthraquinone compounds. The molecular formula of chrysophanol is C₁₅H₁₀O₄, the molecular weight is 254.2 g/mol, and the melting point is 196°C. Chrysophanol is commonly referred to as chrysophanic acid; this terminology is often used interchangeably in scientific literature and herbal medicine contexts.

It is a crystalline solid, occurring as a golden yellow or brown powder, and exhibits maximum UV absorption at 225, 257, 277, 287, and 428 nm. The solubility of chrysophanol in water is poor; the aqueous solution is yellow but turns red with the addition of an alkali or concentrated sulfuric acid. It is a pale orange-yellow microcrystalline powder, odorless and tasteless, which on exposure to air turns a brownish-yellow color.

Other synonyms and identifiers used in the literature include: 3-methylchrysazin; chrysophal; C.I. 75400; NSC 37132; and CAS registry number 481-74-3. According to ChEBI, it is a trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3.

2. Natural Sources and Distribution

Chrysophanol is a tricyclic aromatic quinone distributed across the plant and animal kingdoms as well as in the microbial world. As of date, it has been reported in 14 genera from different families and in more than 65 species.

To date, it is known to be present in various families, such as Polygonaceae, Rhamnaceae, Fabaceae, Liliaceae, Asphodelaceae, Euphorbiaceae, Meliaceae, Podocarpaceae, Picramniaceae, and Hemerocallidaceae.

Key plant sources include:

Rheum species (rhubarb): Chrysophanic acid is a natural anthraquinone isolated from plants of the Rheum genus, which is commonly used in Traditional Chinese Medicine (TCM). In Rheum officinale, chrysophanol is the most abundant free anthraquinone compound. The most intake is from consumption of rhubarb.
Cassia / Senna species: Chrysophanol is a naturally occurring anthraquinone derived from various traditional Chinese herbs, including Rhei Radix et Rhizoma, Sennae Folium, and Cassiae Semen. It is considered a quality control marker in some species of the genus Cassia, belonging to Fabaceae.
Rhamnus (buckthorn): Chrysophanol is primarily sourced from the roots of plants belonging to the Rhamnus genus, especially Rhamnus palmatus, Rhamnus japonica, and Rhamnus frangula—commonly known as buckthorns. The presence of chrysophanol has also been documented in the bark of some species of Rhamnus, a member of Rhamnaceae.
Aloe vera: Chrysophanol has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.
Polygonum multiflorum and Cassia obtusifolia: Chrysophanol (also known as chrysophanic acid and 1,8-dihydroxy-3-methyl-anthraquinone) is an anthraquinone component extracted from various herbs, such as Rheum palmatum L., Polygonum multiflorum, and Cassia obtusifolia.
Andira araroba (Goa tree / araroba): Araroba is remarkable for occasionally yielding from 80 to 85 per cent of chrysophanic acid, as shown by Attfield in 1875. Chrysarobin is a methyl trioxyanthracene that exists as a glucoside in the plant but is gradually oxidized to chrysophanic acid (a dioxy-methyl anthraquinone) and glucose.
Lichens: A few lower plants, particularly lichens such as Asahinea chrysantha belonging to Parmeliaceae, also efficiently synthesize a wide range of anthraquinones.

Beyond the plant kingdom: In fungi, chrysophanol was first reported from Penicillium islandicum Sopp (ATCC 28431). It has been extensively explored in endosymbiotic fungi of marine organisms and plants. Chrysophanol was also reported in the ethanolic extract of bee propolis (bee glue), a sticky resinous material collected by honeybees to architect and insulate their hives as well as to protect the hive from microbial growth. It was also reported to be present in the shield of some insects, which is a waxy layer used for defense; insects synthesize it as an adaptation against predators.

3. Biosynthesis and Common Preparations

Chrysophanol is naturally synthesized via the PMA or octaketide pathway; eight units of acetyl CoA are condensed by polyketide synthase. Leistner and Zenk reported that chrysophanol is synthesized in fungi through the PMA pathway, whereas in plants it is synthesized through both shikimate and PMA pathways.

The folding of the octaketide chain varies in an organism-dependent manner: the "F" pattern is found in fungi, insects, and plants, whereas the "S" pattern is present in bacteria. These differences in folding patterns are unique in nature. Chrysophanol is the first polyketide that has been reported to be biosynthesized in an organism-specific manner.

Common forms and preparations in which chrysophanol has been used include:

Topical ointments: Chrysophanic acid has been chiefly employed as a local application in certain cutaneous affections, as mentagra, eczema, herpes tonsurans, herpes circinati, psoriasis, acne rosacea, etc.
Goa powder / araroba extracts: Goa powder or araroba is contained in the trunk of the araroba tree, filling crevices in the heartwood. It is a morbid product in the tree and yields to hot chloroform 50% of a substance known officially as chrysarobin.
Isolated pure compound for research and pharmaceutical applications: Extracted directly from plant and fungal sources, natural chrysophanol retains its original biochemical profile.
Nanoparticle formulations: Nanomedicines deliver a drug systematically into blood plasma and ultimately improve its bioavailability. Gold chrysophanol decorated with poly(DL-lactide-co-glycolide) nanoparticles has been synthesized and tested against prostate cancer.
Traditional decoctions and TCM preparations: including Rhei Radix et Rhizoma (Da Huang) and multi-herb formulas. Rhei Radix et Rhizoma was used for centuries in different fields including pharmaceutical, health care, and cosmetics.

4. Traditional and Historical Use

4.1 Traditional Chinese Medicine (TCM) and Korean Medicine (TKM)

The traditional Chinese and Korean medicinal systems provide evidence of the beneficial effects of chrysophanol on human health. Rheum palmatum L. was a traditional Chinese medicine used for centuries in different fields, including pharmaceutical, health care, and cosmetics.

In TCM, the seeds of Cassia species were employed with the expectation that their intake could cure skin diseases like ringworm, itch, and psoriasis, and could also remove intense heat from the liver, improve acuity of sight, and loosen the bowels to relieve constipation. The leaves were employed in weak decoction for treating childhood teething, fever, and constipation.

4.2 Ayurvedic and South Asian Use

The paste of the ground, dried root is used in Ayurveda to treat ringworm and snakebite.

4.3 Western Dermatological Use (19th–Early 20th Centuries)

Chrysophanic acid is a hydroanthraquinone derivative and a major antifungal compound that was traditionally used as the mainstay of antipsoriatic treatment before standard antipsoriatic medications became available.

Dithranol and chrysophanic acid are therapeutic substances in araroba powder that are responsible for success in the treatment of psoriasis and chronic eczema.

A report published in 1879 recorded Dr. I. Neumann's clinical experience: He found it useful not only in psoriasis and parasitic diseases (such as pityriasis versicolor, herpes tonsurans, eczema marginatum) but also in chloasma uterinum, and noted that its effectiveness seemed to be considerably increased by the addition of thymol.

A further clinical report from 1880 by Dr. A. F. Pattee described chrysophanic acid as "one of the most useful and important therapeutical agents in the treatment of certain intractable diseases of the skin, especially those belonging to the scaly order." He treated many cases of psoriasis, herpes, eczema, impetigo, lichen, and pityriasis that had resisted other well-tried means; three cases of more than ten years' duration, whose bodies were almost entirely covered with scales, were reportedly cured after three weeks' treatment.

The general practice amongst modern dermatologists of the early era was to use only chrysophanic acid, which could be applied externally and given by the mouth in cases of psoriasis and chronic eczema. The drug was considered a feeble antiparasitic and was used locally in the treatment of ringworm.

In the Indies, Goa powder was employed for the removal of taenia solium and in the treatment of certain cutaneous maladies.

5. Key Constituents and Related Compounds

While chrysophanol (chrysophanic acid) is itself the primary active compound discussed under the "chrysophanics" umbrella, it co-occurs in source plants alongside other structurally related anthraquinones that contribute to the overall pharmacological profile of crude extracts. In rhubarb root, chrysophanol occurs alongside rhein, emodin, aloe-emodin, and physcion. Structural relationship analysis of anthraquinones suggested that the methyl group on the 3rd position and two hydroxyl groups on the 1st and 8th position of chrysophanol are responsible for its anticancer effects.

A notable derivative, chrysophanol-8-O-glucoside (the glycosidic form), is found in plant tissues and has distinct pharmacological and toxicological properties. Chrysophanol derivatives such as chrysophanol-8-O-glucoside have also been shown to possess anti-coagulant and anti-platelet properties.

Chrysarobin, the precursor in Goa powder, is distinct from chrysophanol: chrysarobin is a methyl trioxyanthracene that exists as a glucoside in the plant but is gradually oxidized to chrysophanic acid and glucose.

6. Established Mechanisms of Action

6.1 Anticancer Mechanisms

Chrysophanol exerts its anticancer effects through the induction of cell cycle arrest, promotion of apoptosis, regulation of autophagy, and initiation of necrosis across various cancer cell lines.

Several studies have demonstrated that chrysophanol exhibits anticancer properties mainly through necrosis, a caspase-independent phenomenon, which triggers an irreversible inflammatory response against tumor cells.

Chrysophanol inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K. In vitro, chrysophanol blocks proliferation of colon cancer cells by inhibiting the EGFR/mTOR pathway.

In breast cancer cell lines MCF-7 and MDA-MB-231, MTT assay and flow cytometric analysis demonstrated that chrysophanol inhibited cell proliferation and cell cycle progression in a dose-dependent manner. The expression of cell cycle-associated cyclin D1 and cyclin E were downregulated while p27 expression was upregulated. Apoptosis levels increased following chrysophanol treatment.

Chrysophanol upregulated caspase-3 and poly(ADP-ribose) polymerase cleavage in breast cancer cell lines. It enhanced the effect of paclitaxel on breast cancer cell apoptosis, and downregulated apoptosis regulator Bcl-2 protein, transcription factor p65, and IκB phosphorylation.

In choriocarcinoma, chrysophanol induced cell apoptosis by regulating production of reactive oxygen species (ROS) through AKT and ERK1/2 signaling pathways.

Chrysophanol promotes cell morphologic changes, induces cell apoptosis through DNA damage, and arrests S phase of the cell cycle in liver cancer.

6.2 Anti-Inflammatory Mechanisms

Anti-inflammatory effects of chrysophanol on dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-induced inflammation have been demonstrated to effectively suppress overall clinical concentrations of moieties, including those of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and cyclooxygenase-2 (COX-2) through the regulation of the NFκB pathway.

Chrysophanol suppressed the expression of the CD40 ligand (CD40L) in activated T cells. Treatment with chrysophanol in Jurkat T cells blocked the NFκB signaling pathway, resulting in the abrogation of MAPK (mitogen-activated protein kinase) in activated T cells.

6.3 Neuroprotective Mechanisms

It was reported that application of chrysophanol in vivo contributed to recovering learning and memory abilities through inhibiting pro-inflammatory cytokines. Chrysophanol could downregulate the death rate of neurons in the hippocampus CA3 region.

Chrysophanol cannot easily cross the blood–brain barrier, resulting in low levels of chrysophanol in the brain tissue. This pharmacokinetic limitation is an important constraint on the neuroprotective effects observed in experimental models.

6.4 Hypolipidemic Mechanisms

Chrysophanol has been shown to be able to be co-administered with atorvastatin to lower cholesterol levels. This is due to the different mechanisms for each, with chrysophanol thought to bind to the stomach to disturb lipid absorption, while atorvastatin decreases cholesterol production in the liver.

Chrysophanol significantly inhibits cholesterol and triglyceride in zebrafish provided with a high fat/cholesterol diet. It might be attributed to the promotive effect on digestion and decreased absorption of dietary lipid; however, the exact mechanism of hypolipidemic activity of chrysophanol is unexplored as of yet.

6.5 Antidiabetic Mechanisms

Chrysophanol was isolated from the leaves of C. acutifolia and showed mild antidiabetic properties in cell culture. Its activity was proposed to be mediated through affecting glucose transport and the tyrosine phosphorylation of the insulin receptor, improving insulin action or insulin-independent effects.

6.6 Nephroprotective Mechanisms

In mouse models, pre-treatment with chrysophanol greatly relieved cisplatin-induced acute kidney injury and improved kidney function and morphology. Mechanistic studies indicated that it might alleviate the injury by inhibiting oxidative stress, apoptosis, and the IKKβ/IκBα/p65/NF-κB inflammation signaling pathway induced by cisplatin.

7. Scientific Evidence by Area of Use

Important overarching caveat: Despite the promising therapeutic potential of chrysophanol, challenges such as poor water solubility, low bioavailability, and safety concerns remain. Comprehensive clinical trials are essential to validate its efficacy and safety. The overwhelming majority of the evidence summarized below derives from in vitro cell studies and animal models; human clinical trial data are essentially absent for chrysophanol as an isolated compound.

7.1 Oncology / Anticancer Activity

Evidence level: Preclinical only (in vitro and animal); no human clinical trials identified.

Chrysophanol is an active compound derived from traditional Chinese medicine known for its potential anticancer properties and selective cytotoxicity against various cancer cell lines, including cervical, gastric, breast, and liver cancers, while sparing non-cancerous cells.

Chrysophanol inhibits cell growth in several cancer cells and regulates genes and proteins involved in controlling apoptosis, cell invasion, metastasis, and cell cycle arrest. In addition, the synergistic effect of chrysophanol combined with other drugs for anticancer purposes is promising and has attracted the attention of researchers.

Researchers found that chrysophanol had antiproliferative activity on MCF-7 breast cancer cells, gastric cancer 7901 cells, melanoma A375 cells, and oophoroma SKOV-3 cells.

In glioma research, glioma cell lines U251 and SHG-44 were adopted in experiments; the cells were treated with chrysophanol at different concentrations (0, 10, 20, 50, 100, and 200 μM) for 48 hours.

The review literature discusses the challenges of chrysophanol in pharmacokinetics and safety, suggesting future research is needed to reveal its full anticancer potential. No randomized controlled trials or human cohort studies have tested chrysophanol as an isolated anticancer agent.

7.2 Inflammation and Immune Modulation

Evidence level: Preclinical (in vitro and animal); no human clinical trials identified.

Findings in recent years have indicated that chrysophanol, as a potential therapeutic, could be used for treating inflammation-associated diseases, such as sepsis, atopic dermatitis, and ulcerative colitis.

In immunological research, treatment with 40 μM chrysophanol for 24 hours in Jurkat T cells was assessed for cytotoxic effects; the data obtained suggest that chrysophanol not only has anticancer activities in various cells but also shows anti-inflammatory effects.

7.3 Neurology and Neuroprotection

Evidence level: Preclinical (animal models and cell culture); no human clinical trials identified.

Pharmacological effects indicate that chrysophanol has value in the prevention and treatment of certain diseases, including Alzheimer's disease (AD). In a rat model of diabetes-depression comorbidity, chrysophanol treatment restored serum brain-derived neurotrophic factor (BDNF) levels (p < 0.01) and ameliorated dyslipidemia (total cholesterol: p < 0.05).

The compound's pharmacokinetics reveal high absorption but poor blood-brain barrier penetration, affecting its neuroprotective potential. This constitutes a significant obstacle to translating in vitro and animal neuroprotective findings to human outcomes.

7.4 Metabolic and Lipid Disorders

Evidence level: Animal studies; no human clinical trials identified.

Chrysophanol has value in the study of atherosclerosis and diabetes and diabetic complications. Animal experimental work and cell culture studies have demonstrated activity, but there are no published human trials of chrysophanol as an isolated compound for these conditions.

7.5 Dermatology (Psoriasis, Eczema, Ringworm)

Evidence level: Historical clinical reports (late 19th century); no modern randomized controlled trials of isolated chrysophanol identified.

Chrysophanic acid was traditionally used as the mainstay of antipsoriatic treatment before standard antipsoriatic medications became available. The historical clinical literature from the 1870s–1880s describes topical application in psoriasis and related conditions, but these are observational case reports, not controlled trials, and predate modern clinical trial methodology.

7.6 Antimicrobial Activity

Evidence level: In vitro microbiological studies; no human clinical trials identified.

The minimum inhibitory concentration (MIC) values of chrysophanol for E. coli (Colon bacillus) and Neisseria gonorrhoeae were 3.13 μg/ml and more than 75 μg/ml, respectively.

7.7 Kidney Protection

Evidence level: Animal (mouse) and cell culture models only.

As noted above under mechanisms, chrysophanol demonstrated nephroprotective activity in cisplatin-treated C57BL/6 mice and in human proximal tubule epithelial cells (HK2) in cell culture. The cell viability of HK2 cells reduced by cisplatin was partially rescued by chrysophanol pre-incubation. No human nephroprotective trials have been identified.

8. Pharmacokinetics

Numerous pre-clinical pharmacokinetic studies revealed that chrysophanol exhibited better absorption and slower elimination at higher concentrations than some other anthraquinones obtained from the rhubarb family.

Studies of plasma protein binding (PPB) rate in rat plasma, human plasma, and bovine serum albumin reported values of 83 ± 2%, 88 ± 3%, and 58 ± 3%, respectively. The PPB rate is an important parameter that strongly influences the bioavailability, metabolism, and tissue distribution of a drug. The high PPB rate of chrysophanol could be responsible for its tissue distribution in the body.

The levels of chrysophanol were found to be higher in kidneys than in liver, suggesting that it is eliminated by excretion rather than by being metabolized. Chrysophanol cannot easily cross the blood–brain barrier, resulting in low levels in brain tissue.

Low lipophilicity and low log P values enhance the absorption or permeation of a drug. The chemical properties of chrysophanol suggest that it is suitable as an orally active drug. However, chrysophanol is slightly soluble in water.

In Dachengqi Decoction (comprising Radix et Rhizoma Rhei, Magnolia officinalis, Fructus Aurantii Immaturus, and Natrii Sulfas), the elimination of chrysophanol will be slower. This illustrates how the co-formulation context of TCM preparations influences the pharmacokinetics of individual constituent compounds.

9. Dosage Forms and Reported Doses

There is no established human therapeutic dosage for isolated chrysophanol. The following dosages have been reported in experimental or historical contexts only:

Historical topical dermatological dose (19th century): Thirty grains of the acid was the smallest quantity used topically, and one hundred and twenty grains is the largest that would be required.
Historical oral dose (early clinical reports): Chrysophanic acid could be given by the mouth in doses of about one grain in cases of psoriasis and chronic eczema.
In vitro cell studies: Cells were treated with chrysophanol at different concentrations (0, 10, 20, 50, 100, and 200 μM) for 48 hours in glioma studies.
Animal (fish) immune study: The first report on the positive influence of chrysophanic acid in Catla catla on innate and adaptive immune responses found the optimum level of chrysophanic acid to be 4 mg kg⁻¹, which manifested during the 2nd week of treatment.
Rat NOAEL (rhubarb preparations): After experimenting on rats, it was announced that with long-term use of Rhubarb, the NOAEL was 2.5 g/kg/d in rats (equivalent dose in the human body was 0.4 g/kg/d).

10. Body Systems and Health Areas of Association

These pharmacological effects indicate that chrysophanol has value in the prevention and treatment of certain diseases, including cancer, atherosclerosis, asthma, diabetes and diabetic complications, Alzheimer's disease (AD), atopic dermatitis, and osteoarthritis.

Based on the peer-reviewed evidence base, chrysophanol has been studied in relation to the following body systems:

Dermatological system: psoriasis, eczema, ringworm (dermatophytosis), chloasma, acne rosacea, herpes tonsurans — primarily historical topical use and in vitro antifungal data.
Oncological/cellular: colon, liver, breast, cervical, gastric, ovarian, prostate, lung (A549), glioma, and choriocarcinoma cancer cell lines — all preclinical only.
Hepatic system: hepatoprotective effects in some models, but also hepatotoxic potential (see Safety section).
Renal system: nephroprotective activity in cisplatin toxicity models; simultaneously, nephrotoxic risk.
Nervous system: hippocampal neuroprotection, antidepressant activity in rodent models, Alzheimer's disease models.
Metabolic/endocrine system: hypolipidemic, antidiabetic, and anti-obesity activity, primarily in animal models.
Immune system: modulation of T-cell activation, NF-κB signaling, cytokine suppression.
Gastrointestinal system: antiulcer activity; laxative effects from rhubarb-family sources.
Cardiovascular system: anti-platelet and anti-coagulant properties noted for derivatives; anti-atherosclerotic research.

11. Safety Considerations and Known Interactions

11.1 Hepatotoxicity

Chrysophanol has obvious hepatotoxicity and nephrotoxicity, and pharmacokinetics indicate that the use of chrysophanol in combination with other drugs can reduce toxicity and enhance efficacy.

Chrysophanol has shown both hepatotoxic and hepatoprotective effects. Based on summarizing the literature, this is believed to be mainly related to the concentration of chrysophanol and the time of administration. Long-term administration and rapid administration of large doses may cause liver damage.

Anthraquinones, chrysophanol derivatives among them, have been shown to be hepatotoxic. They can cause apoptosis in normal human liver cells.

11.2 Mitochondrial and Cellular Toxicity

Chrysophanol-8-O-glucoside (a glycosidic derivative) has strong hepatotoxicity and can lead to increased LDH leakage and ROS, and decreased GSH and mitochondrial membrane potential (MMP) in L-02 hepatocytes. It can lead to abnormal oxidative phosphorylation by inhibiting the function of mitochondrial complexes, resulting in decreased mitochondrial membrane potential, increased reactive oxygen species, and eventually mitochondrial damage and apoptosis.

Chrysophanol derivatives also have potential to cause abnormal oxidative phosphorylation, which can result in decreased mitochondrial membrane potential, an increase in abundance of reactive oxygen species, and ultimately will lead to mitochondrial damage and eventual apoptosis.

11.3 Gastrointestinal and Systemic Adverse Effects

Animals administered chrysophanol had adverse reactions such as diarrhea, abdominal pain, vomiting, nausea, and bowel sounds.

In historical clinical use, chrysophanic acid was noted to be a powerful irritant of the skin and mucous membranes. Given internally in crude form it has caused nausea, vomiting, and purging.

Internally, 200 mg can produce diarrhea, nausea, and nephritis. Goa powder is irritant to the respiratory tract. In industrial accidents, chrysophanic acid has produced conjunctivitis and keratitis.

11.4 Mutagenicity

Chrysophanol demonstrates moderate toxicity with significant mutagenicity in specific assays, necessitating further in vivo studies.

11.5 Skin Staining

It stains the skin and linen a deep yellow or brown, a coloration which may be removed by caustic alkali in weak solution.

11.6 Drug Interactions

Chrysophanol has been shown to be able to be co-administered with atorvastatin to lower cholesterol levels, due to the different mechanisms for each — chrysophanol thought to bind to the stomach to disturb lipid absorption, while atorvastatin decreases cholesterol production in the liver. This co-administration has only been studied experimentally, not in human clinical trials.

In Dachengqi Decoction, the elimination of chrysophanol will be slower, illustrating that herbal co-formulations can meaningfully alter chrysophanol's pharmacokinetics and potentially its safety profile.

The pharmacokinetics and toxicity studies on chrysophanol demand further investigations for it to be used as a drug.

11.7 Knowledge Gaps

Future research directions include how the concentration of chrysophanol affects pharmacological effects and toxicity, and the mechanism of synergy between chrysophanol and other drugs. The pharmacokinetics and toxicity studies on chrysophanol demand further investigations for it to be used as a drug.

References

Health Conditions

Health conditions that Chrysophanics may help support.

No conditions available.

Body Systems

Body systems that Chrysophanics may help support.

No body systems available.